Exenatide Injection Articles
Higher risk of pancreatitis for those taking new class of diabetes drugs, Johns Hopkins study finds
26 February 2013
Amylin seduced by $5.3 billion bid from Bristol-Myers; AstraZeneca chips in for share of the action
2 July 2012
EMA advisory backs Humira for UC and expanded use of Byetta
20 February 2012
Amylin 4th-qtr loss widens on charges
7 February 2012
Amylin diabetes drug exenatide deal with Eli Lilly terminated, with $1.45 billion settlement to Lilly
9 November 2011
Amylin and Lilly’s diabetes drug Byetta has rapid, powerful anti-inflammatory effect
4 November 2011
Type 2 diabetes agents - DPP-IV inhibitors - will be main beneficiaries of pioglitazone problems
1 August 2011
Amylin’s diabetes drug Bydureon approval delayed again by US FDA call for more clinical data; 3rd qtr sales data
20 October 2010
Impact of Avandia restrictions could benefit Januvia, Byetta and Victoza, US physician survey reveals
7 October 2010
Type 2 diabetes drug market to nearly double to $36 billion in 2019, boosted by news drugs; research shows many patients not taking their insulin
23 September 2010
US FDA exec questions safety of Lilly and Amylin’s Byetta, saying it may pose cancer risk
12 April 2010
FDA approves Novo Nordisk’s new type 2 diabetes drug Victoza
26 January 2010
US FDA warns four drugmakers on inaccurate promotion
13 January 2010
Roche/Ipsen’s taspoglutide meets Ph III primary endpoints against Lantus and placebo in patients with high BMI
18 December 2009
US FDA revises Byetta label to reflect possible kidney problems
3 November 2009
Ipsen launch’s Dysport in USA, updates on taspoglutide
29 October 2009
Novo Nordisk
7 May 2009
Exenatide once weekly NDA submitted to FDA
6 May 2009
Icahn pushing Lilly to buy Amylin?
21 April 2009
Diabetes sales weaken with economy
20 April 2009
Amylin narrows 1st-qtr loss 34% to $47M
20 April 2009
Amylin up 8% as Byetta cleared of CV health risk
27 March 2009
Stock Commentary - New York week to Mar 16, 2009
23 March 2009
Stock Commentary - New York week to Mar 2, 2009
9 March 2009
Stock Commentary - New York week to Feb 23, 2009
2 March 2009
Amylin's loss deeper on Byetta worries
9 February 2009
Stock Commentary - New York week to Jan 19, 2009
26 January 2009
Stock Commentary - New York week to Dec 15, 2008
22 December 2008
Lilly expects to report loss for full-year 2008 but 2009 guidance unaffected by forex
22 December 2008
FDA review of wider Byetta label delayed
15 December 2008
Stock Commentary - New York week to Dec 8, 2008
15 December 2008
Stock Commentary - New York week to Nov 17, 2008
24 November 2008
Stock Commentary - New York week to Nov 10, 2008
17 November 2008
Amylin shares plunge 26% on possible Byetta LAR US approval delay
10 November 2008
Amylin hits 6-year low on Byetta LAR concerns
3 November 2008
Stock Commentary - New York week to Oct 27, 2008
3 November 2008
Stock Commentary - New York week to Oct 20, 2008
27 October 2008
Amylin and Lilly enter supply agreement for Byetta once weekly
27 October 2008
Novo's liraglutide achieves greater glycemic control than Amylin/Lilly's Byetta in LEAD 6
27 October 2008
Byetta: better post-meal glucose reduction than Januvia
15 September 2008
Liraglutide improves multiple endpoints in LEAD-4
15 September 2008
Stock Commentary - New York week to Sept 1, 2008
8 September 2008
Stock Commentary - New York week to Aug 25, 2008
1 September 2008
UPDATE: FDA considering strong warning on Byetta; potential fall-out for all GLP-1s
1 September 2008
Amylin's 2nd-qtr 2008 loss widens to $64.8M
4 August 2008
Stock Commentary - New York week to June 16, 2008
23 June 2008
Liraglutide superior to Byetta: LEAD study
16 June 2008
Amylin/Lilly's Byetta achieves glycemic control
16 June 2008
Stock Commentary - New York week to June 9, 2008
16 June 2008
Stock Commentary - New York week to March 24, 2008
31 March 2008
Stock Commentary - New York week to March 3, 2008
10 March 2008
Stock Commentary - New York week to Feb 18, 2008
25 February 2008
Amylin's loss for 4th-qtr 2007 worsens 32%
4 February 2008
Lilly to invest in Italian insulin production
14 January 2008
Amylin/ lilly plan Byetta monotherapy filing
17 December 2007
Raft of pending patent expiries threaten cardiovascular blockbusters
10 December 2007
Amylin's 3rd-qtr net loss narrows to $39.8M
29 October 2007
FDA warns on Byetta's pancreatitis risk
22 October 2007
Stock Commentary - New York week to July 30, 2007
6 August 2007
SMC OKs Lilly's Byetta as insulin alternative
23 July 2007
Stock Commentary - New York week to July 9, 2007
16 July 2007
Lilly launches diabetes drug Byetta in the UK
14 May 2007
Amylin's 1st-qtr 2007 net loss narrows 27.2%
23 April 2007
Lilly's 1st-qtr 2007 earnings drop 39%
23 April 2007
Amylin's loss narrows 13.1% in 4th-qtr
12 February 2007
Stock Commentary - New York week to Feb 5, 2007
12 February 2007
Amylin/Lilly's Byetta comparable to insulin
7 February 2007
Stock Commentary - New York week to Aug 15
29 January 2007
Stock Commentary - New York week to Jan 15, 2007
22 January 2007
Byetta gets FDA OK for use with TZD
8 January 2007
Lilly reiterates 2006/07 guidance, disappoints
18 December 2006
Stock Commentary - New York week to Nov 20, 2006
27 November 2006
Lilly/Amylin's Byetta cleared in Europe
27 November 2006
Eli Lilly will not cut back in France
20 November 2006
Lilly's 3rd-qtr 2006 profit rises 10% on Zyprexa
30 October 2006
Amylin's losses down 37% in 3rd-qtr
30 October 2006
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
